Summary
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
History
After being founded in 2015 and headquartered in Jena, Germany, InflaRx raised significant venture capital funding as well as public funding to support the clinical development of IFX-1 and its operating expenses.
Mission
At InflaRx, we are devoted to the design and development of innovative medicines targeting the innate immune system for patients with severe unmet medical needs.
Vision
We strive to become an industry-leading biopharmaceutical organization with a portfolio of best-in-class therapeutics that fulfill unmet medical needs and make genuine contributions to patient health and well-being.
Key Team
Ms. Nicole Bertsch (Sr. Director & Head of HR)
Ms. Evelyn Roth-Geissler Ph.D. (VP & Head of Clinical Operations)
Dr. Maria Habel PH.D. (Head of Preclinical R&D)
Dr. Bruce P. Burnett Ph.D. (VP & Head of Medical Affairs)
Mr. Christian Schmid (VP and Head of Legal Affairs & Corp. Counsel)
Mr. Kafi Boaten (Sr. Director and Head of Supply & Clinical Trial Supplies)
Mr. Peter Hurt Ph.D. (Sr. Director and Head of Drug Safety & Pharmacovigiliance)
Recognition and Awards
InflaRx has won numerous awards for our efforts in developing innovative medicines, including the JUVE Award for Most Innovative Start-Up of 2018.
References
